Beacon's AI platform for brain data enables and accelerates new treatments that transform the lives of patients with neurological and psychiatric disease. Through novel machine learning algorithms, enormous datasets, and advances in software engineering, we are changing the way patients are treated for disorders of the brain.
Location: United States, Massachusetts, Boston
Employees: 11-50
Total raised: $27M
Founded date: 2019
Investors 2
| Date | Name | Website |
| 26.09.2021 | Synetro Gr... | synetro.co... |
| - | Indicator ... | indicatorv... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.11.2021 | Series A | $27M | - |
Mentions in press and media 10
| Date | Title | Description |
| 24.04.2024 | DATAcc by DiMe Launches Core Measures for Sleep | Core sleep measures and resources will help transform sleep research and care to advance the treatment of multiple disease areas BOSTON, April 24, 2024 /PRNewswire/ -- Today, the Digital Health Measurement Collaborative Community (DATAcc) b... |
| 27.03.2024 | BEACON BIOSIGNALS EXPANDS SLEEP ANALYSIS CAPABILITIES WITH FDA CLEARANCE OF SLEEPSTAGEML | MILESTONE BROADENS THE COMPANY'S ANALYSIS PLATFORM, EXTENDING ITS APPLICATION FROM AT-HOME SLEEP MONITORING TO ALSO INCLUDE COMPREHENSIVE COVERAGE OF TRADITIONAL IN-LAB POLYSOMNOGRAPHY. BOSTON, March 27, 2024 /PRNewswire/ -- Beacon Biosigna... |
| 13.07.2023 | Beacon Biosignals Acquires Dreem | Beacon Biosignals, a Boston, MA-based computational neurodiagnostics and electroencephalogram (EEG) analytics company, acquired Dreem, a Paris, France-based company which specializes in at-home sleep monitoring. The amount of the deals as n... |
| 14.11.2021 | Neurotech startup Beacon Biosignals scores $27M to bring AI to EEG analysis | Electroencephalography is a decades-old technique for capturing brain activity, data that are used to evaluate brain disorders. Beacon Biosignals is applying artificial intelligence to these tests, and the neurotechnology startup has found ... |
| 09.11.2021 | Beacon Biosignals Raises $27M in Series A | Beacon Biosignals, a Boston MA-based neurotechnology company, raised $27M in Series A funding. The round, which brought Beacon Biosignals’ total funding to date to $30m, was led by General Catalyst and with participation from Casdin Capital... |
| 09.11.2021 | Chamath Palihapitiya-backed Metromile SPAC fails to live up to its promise | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. When SPAC evangelist Chamath Palihapitiya announced his backing of auto-insurance startup Metromi... |
| 08.11.2021 | Beacon Biosignals raises $27 Million Series A led by General Catalyst to scale its EEG neurobiomarker discovery platform | BOSTON, Nov. 8, 2021 /PRNewswire/ -- Beacon Biosignals, a neurotechnology company applying artificial intelligence to EEG (electroencephalography) to unlock precision medicine for any condition affecting the brain, has announced an oversubs... |
| 08.11.2021 | Beacon Biosignals Secures $27M to Scale EEG Neurobiomarker Discovery Platform | What You Should Know: – Beacon Biosignals, a neurotechnology company applying artificial intelligence to EEG (electroencephalography) to unlock precision medicine for any condition affecting the brain, has announced an oversubscribed $27M S... |
| - | Neurotech startup Beacon Biosignals scores $27M to bring AI to EEG analysis | Electroencephalography is a decades-old technique for capturing brain activity, data that are used to evaluate brain disorders. Beacon Biosignals is applying artificial intelligence to these tests, and the neurotechnology startup has found ... |
| - | Startup with bold goal to establish digital biomarkers for neurological disease diagnosis wins $25M | Artificial intelligence is being leveraged to solve a variety of healthcare challenges, but its greatest promise remains its potential to detect and diagnose diseases better than humans can. The latter is being attempted by NeuraLight, an I... |